Correlation Between Champions Oncology and Lumos Pharma

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Champions Oncology and Lumos Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Champions Oncology and Lumos Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Champions Oncology and Lumos Pharma, you can compare the effects of market volatilities on Champions Oncology and Lumos Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Champions Oncology with a short position of Lumos Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Champions Oncology and Lumos Pharma.

Diversification Opportunities for Champions Oncology and Lumos Pharma

-0.33
  Correlation Coefficient

Very good diversification

The 3 months correlation between Champions and Lumos is -0.33. Overlapping area represents the amount of risk that can be diversified away by holding Champions Oncology and Lumos Pharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Lumos Pharma and Champions Oncology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Champions Oncology are associated (or correlated) with Lumos Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Lumos Pharma has no effect on the direction of Champions Oncology i.e., Champions Oncology and Lumos Pharma go up and down completely randomly.

Pair Corralation between Champions Oncology and Lumos Pharma

Given the investment horizon of 90 days Champions Oncology is expected to generate 3.7 times more return on investment than Lumos Pharma. However, Champions Oncology is 3.7 times more volatile than Lumos Pharma. It trades about 0.08 of its potential returns per unit of risk. Lumos Pharma is currently generating about -0.16 per unit of risk. If you would invest  398.00  in Champions Oncology on August 28, 2024 and sell it today you would earn a total of  20.00  from holding Champions Oncology or generate 5.03% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Champions Oncology  vs.  Lumos Pharma

 Performance 
       Timeline  
Champions Oncology 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Champions Oncology has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable fundamental drivers, Champions Oncology is not utilizing all of its potentials. The recent stock price agitation, may contribute to short-term losses for the retail investors.
Lumos Pharma 

Risk-Adjusted Performance

3 of 100

 
Weak
 
Strong
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Lumos Pharma are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of very weak primary indicators, Lumos Pharma may actually be approaching a critical reversion point that can send shares even higher in December 2024.

Champions Oncology and Lumos Pharma Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Champions Oncology and Lumos Pharma

The main advantage of trading using opposite Champions Oncology and Lumos Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Champions Oncology position performs unexpectedly, Lumos Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lumos Pharma will offset losses from the drop in Lumos Pharma's long position.
The idea behind Champions Oncology and Lumos Pharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

Other Complementary Tools

Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Fundamental Analysis
View fundamental data based on most recent published financial statements
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins